thanks just checked previous filings
looks like the sunpill was a bummer
It is a far cry from the 8 million suggested by the boss
I am still very interested in the snake pain reliever though.
Net Revenues Total net revenues increased $14,231 or 32.3%, to $58,224 (Q109) from $43,993 (Q108). Our efforts redirecting and allocating available resources to concentrate on the distribution of the SunPill?, a defense system that protects the skin from the damaging effects of the sun, and the distribution of AlGal, a tasteless, odorless form of Omega 3 fatty acid, which is used as a food additive has began to yield results. No sales from AlGal products were generated in Q109 however the bulk of our increase in revenue was generated by sales of the SunPill?. We will continue to market our proprietary Clinical NSPs - XenaCor, XenaTri and XenaZymePlus distributed through the mail to our existing customer base.
The Company has approximately $300,000 of product placed with customers, however sales of SunPill remained suppressed during Q109 as a result of the Company's inability to raise sufficient cash to effect the marketing promotions necessary to generate significant sell thru.
